{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T12:02:56Z","timestamp":1792324976089,"version":"4.4.0"},"reference-count":95,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Eye Research"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.exer.2025.110395","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T06:45:10Z","timestamp":1745304310000},"page":"110395","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Immune-related biomarkers in the neuromyelitis optica spectrum disorder; pathogenesis and therapeutic approaches"],"prefix":"10.1016","volume":"256","author":[{"given":"Jingyong","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Dan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiguo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8314-774X","authenticated-orcid":false,"given":"Zhuyang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exer.2025.110395_bib1","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2147\/NDT.S185336","article-title":"Cytokines and chemokines expression in serum of patients with neuromyelitis optica","volume":"15","author":"Ai","year":"2019","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"10.1016\/j.exer.2025.110395_bib2","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1212\/WNL.0000000000000317","article-title":"Efficacy of the anti\u2013IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study","volume":"82","author":"Araki","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.exer.2025.110395_bib3","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1474-4422(19)30488-0","article-title":"Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study","volume":"19","author":"Armangue","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.exer.2025.110395_bib4","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0006-8993(00)02807-9","article-title":"Intrathecal anti-IL-6 antibody and IgG attenuates peripheral nerve injury-induced mechanical allodynia in the rat: possible immune modulation in neuropathic pain","volume":"879","author":"Arruda","year":"2000","journal-title":"Brain Res."},{"key":"10.1016\/j.exer.2025.110395_bib5","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1080\/14712598.2021.1884223","article-title":"Targeting the complement system in neuromyelitis optica spectrum disorder","volume":"21","author":"Asavapanumas","year":"2021","journal-title":"Expet Opin. Biol. Ther."},{"key":"10.1016\/j.exer.2025.110395_bib6","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.it.2011.03.008","article-title":"Interferon-\u03b2 exacerbates Th17-mediated inflammatory disease","volume":"32","author":"Axtell","year":"2011","journal-title":"Trends Immunol."},{"key":"10.1016\/j.exer.2025.110395_bib7","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1001\/jamaneurol.2013.1246","article-title":"Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy","volume":"70","author":"Ayzenberg","year":"2013","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.exer.2025.110395_bib8","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00415-015-7991-1","article-title":"Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study","volume":"263","author":"Ayzenberg","year":"2016","journal-title":"J. Neurol."},{"key":"10.1016\/j.exer.2025.110395_bib9","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00415-009-0139-4","article-title":"Narcolepsy as an initial manifestation of neuromyelitis optica with antiaquaporin-4 antibody","volume":"256","author":"Baba","year":"2009","journal-title":"J. Neurol."},{"key":"10.1016\/j.exer.2025.110395_bib10","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jneuroim.2017.04.001","article-title":"Expansion of IL-6+ Th17-like cells expressing TLRs correlates with microbial translocation and neurological disabilities in NMOSD patients","volume":"307","author":"Barros","year":"2017","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.exer.2025.110395_bib11","first-page":"75","article-title":"Anti-aquaporin-4 antibodies in neuromyelitis optica: how to prove their pathogenetic relevance?","volume":"15","author":"Bradl","year":"2008","journal-title":"Int. MS J."},{"key":"10.1016\/j.exer.2025.110395_bib12","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/WCO.0000000000000551","article-title":"Mechanisms for lesion localization in neuromyelitis optica spectrum disorders","volume":"31","author":"Bradl","year":"2018","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.exer.2025.110395_bib13","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.msard.2019.01.047","article-title":"Foxp3+ regulatory T cells expression in neuromyelitis optica spectrum disorders","volume":"30","author":"Brill","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.exer.2025.110395_bib14","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s00415-020-09716-4","article-title":"The clinical profile of NMOSD in Australia and New Zealand","volume":"267","author":"Bukhari","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.exer.2025.110395_bib15","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s40364-024-00687-6","article-title":"Unveiling the role of histone deacetylases in neurological diseases: focus on epilepsy","volume":"12","author":"Cao","year":"2024","journal-title":"Biomark. Res."},{"key":"10.1016\/j.exer.2025.110395_bib16","article-title":"Towards human-like walking with biomechanical and neuromuscular control features: personalized attachment point optimization method of cable-driven exoskeleton","volume":"16","author":"Chen","year":"2024","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.exer.2025.110395_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.154887","article-title":"Quercetin: a promising therapy for diabetic encephalopathy through inhibition of hippocampal ferroptosis","volume":"126","author":"Cheng","year":"2024","journal-title":"Phytomedicine"},{"key":"10.1016\/j.exer.2025.110395_bib18","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1073\/pnas.1017385108","article-title":"Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica","volume":"108","author":"Chihara","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.exer.2025.110395_bib19","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s10072-018-3248-y","article-title":"The IL-10-producing regulatory B cells (B10 cells) and regulatory T cell subsets in neuromyelitis optica spectrum disorder","volume":"39","author":"Cho","year":"2018","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.exer.2025.110395_bib20","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.exer.2025.110395_bib21","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41582-020-0400-0","article-title":"Complement in neurological disorders and emerging complement-targeted therapeutics","volume":"16","author":"Dalakas","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.exer.2025.110395_bib22","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.msard.2019.06.018","article-title":"TLR-2 and TLR-4 agonists favor expansion of CD4+ T cell subsets implicated in the severity of neuromyelitis optica spectrum disorders","volume":"34","author":"Dias","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.exer.2025.110395_bib23","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3389\/fneur.2018.00217","article-title":"MOG-IgG-associated optic neuritis, encephalitis, and myelitis: lessons learned from neuromyelitis optica spectrum disorder","volume":"9","author":"Dos Passos","year":"2018","journal-title":"Front. Neurol."},{"key":"10.1016\/j.exer.2025.110395_bib24","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00415-011-6240-5","article-title":"A differential diagnosis of central nervous system demyelination: beyond multiple sclerosis","volume":"259","author":"Eckstein","year":"2012","journal-title":"J. Neurol."},{"key":"10.1016\/j.exer.2025.110395_bib25","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1177\/1352458512457720","article-title":"Neuropathic pruritus (itch) in neuromyelitis optica","volume":"19","author":"Elsone","year":"2013","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.exer.2025.110395_bib26","doi-asserted-by":"crossref","first-page":"355","DOI":"10.34133\/research.0355","article-title":"Orexin neurons to sublaterodorsal tegmental nucleus pathway prevents sleep onset REM sleep-like behavior by relieving the REM sleep pressure","volume":"7","author":"Feng","year":"2024","journal-title":"Research"},{"key":"10.1016\/j.exer.2025.110395_bib27","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1177\/1352458516669002","article-title":"Plasma complement biomarkers distinguish multiple sclerosis and neuromyelitis optica spectrum disorder","volume":"23","author":"Hakobyan","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.exer.2025.110395_bib28","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1001\/archneurol.2009.188","article-title":"Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4\u2013expressing cells","volume":"66","author":"Hinson","year":"2009","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.exer.2025.110395_bib29","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00401-020-02132-y","article-title":"The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody","volume":"139","author":"H\u00f6ftberger","year":"2020","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.exer.2025.110395_bib30","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1001\/jamaneurol.2014.2057","article-title":"Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder","volume":"71","author":"Huh","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.exer.2025.110395_bib31","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/archneur.65.11.noc80069","article-title":"Treatment of neuromyelitis optica with rituximab","volume":"65","author":"Jacob","year":"2008","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.exer.2025.110395_bib32","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jns.2011.03.038","article-title":"Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures","volume":"306","author":"Jarius","year":"2011","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.exer.2025.110395_bib33","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/ana.26226","article-title":"Complement activation is a prominent feature of MOGAD","volume":"90","author":"Keller","year":"2021","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.exer.2025.110395_bib34","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1212\/WNL.0000000000001367","article-title":"MRI characteristics of neuromyelitis optica spectrum disorder: an international update","volume":"84","author":"Kim","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.exer.2025.110395_bib35","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1001\/archneurol.2012.112","article-title":"Painful tonic spasm in neuromyelitis optica: incidence, diagnostic utility, and clinical characteristics","volume":"69","author":"Kim","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.exer.2025.110395_bib36","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1177\/1352458512439439","article-title":"Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?","volume":"18","author":"Kim","year":"2012","journal-title":"Mult. Scler."},{"key":"10.1016\/j.exer.2025.110395_bib37","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1177\/1352458515613165","article-title":"Change in autoantibody and cytokine responses during the evolution of neuromyelitis optica in patients with systemic lupus erythematosus: a preliminary study","volume":"22","author":"Kovacs","year":"2016","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.exer.2025.110395_bib38","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jneuroim.2012.09.002","article-title":"Increase of complement fragment C5a in cerebrospinal fluid during exacerbation of neuromyelitis optica","volume":"254","author":"Kuroda","year":"2013","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.exer.2025.110395_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2024.155635","article-title":"Curcumin-primed olfactory mucosa-derived mesenchymal stem cells mitigate cerebral ischemia\/reperfusion injury-induced neuronal PANoptosis by modulating microglial polarization","volume":"129","author":"Lan","year":"2024","journal-title":"Phytomedicine"},{"key":"10.1016\/j.exer.2025.110395_bib40","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.exer.2025.110395_bib41","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.exer.2025.110395_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainresbull.2024.111045","article-title":"Simvastatin alleviates glymphatic system damage via the VEGF-C\/VEGFR3\/PI3K-Akt pathway after experimental intracerebral hemorrhage","volume":"216","author":"Liao","year":"2024","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.exer.2025.110395_bib43","doi-asserted-by":"crossref","DOI":"10.1111\/cns.70042","article-title":"Autoimmune astrocytopathy double negative for AQP4\u2010IgG and GFAP\u2010IgG: retrospective research of clinical practice, biomarkers, and pathology","volume":"30","author":"Lin","year":"2024","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.exer.2025.110395_bib44","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/bpa.12099","article-title":"The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica","volume":"24","author":"Lucchinetti","year":"2014","journal-title":"Brain Pathol."},{"key":"10.1016\/j.exer.2025.110395_bib45","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/brain\/awf151","article-title":"A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica","volume":"125","author":"Lucchinetti","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.exer.2025.110395_bib46","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3389\/fphar.2019.00395","article-title":"Apelin-13 suppresses neuroinflammation against cognitive deficit in a streptozotocin-induced rat model of Alzheimer's disease through activation of BDNF-TrkB signaling pathway","volume":"10","author":"Luo","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.exer.2025.110395_bib47","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1136\/jnnp-2014-308095","article-title":"Epstein-barr virus persistence and reactivation in neuromyelitis optica","volume":"86","author":"Masuda","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"10.1016\/j.exer.2025.110395_bib48","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","article-title":"Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy","volume":"71","author":"Mealy","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.exer.2025.110395_bib49","article-title":"Update on biomarkers in neuromyelitis optica","volume":"2","author":"Melamed","year":"2015","journal-title":"Neuroimmunol. Neuroinflammation"},{"key":"10.1016\/j.exer.2025.110395_bib50","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/nyas.12118","article-title":"Immunology of neuromyelitis optica: a T cell\u2013B cell collaboration","volume":"1283","author":"Mitsdoerffer","year":"2013","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.exer.2025.110395_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1090548","article-title":"Complement biomarkers reflect the pathological status of neuromyelitis optica spectrum disorders","volume":"14","author":"Miyamoto","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.exer.2025.110395_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2023.578065","article-title":"A novel rare variant of CNPY3 from familial NMOSD impairs the TLR-mediated immune response","volume":"377","author":"Mo","year":"2023","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.exer.2025.110395_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e12132","article-title":"AQP4 as a vintage autoantigen: what do we know till now?","volume":"8","author":"Munera","year":"2022","journal-title":"Heliyon"},{"key":"10.1016\/j.exer.2025.110395_bib54","doi-asserted-by":"crossref","first-page":"8560","DOI":"10.3390\/ijms21228560","article-title":"TLR2 deficiency exacerbates imiquimod-induced psoriasis-like skin inflammation through decrease in regulatory T cells and impaired IL-10 production","volume":"21","author":"Nakao","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.exer.2025.110395_bib55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008622","article-title":"TLR2 and endosomal TLR-mediated secretion of IL-10 and immune suppression in response to phagosome-confined Listeria monocytogenes","volume":"16","author":"Nguyen","year":"2020","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.exer.2025.110395_bib56","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jneuroim.2014.07.001","article-title":"Complement activation in patients with neuromyelitis optica","volume":"274","author":"Nytrova","year":"2014","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.exer.2025.110395_bib57","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1474-4422(12)70133-3","article-title":"Aquaporin 4 and neuromyelitis optica","volume":"11","author":"Papadopoulos","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.exer.2025.110395_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2025.102665","article-title":"Quercetin-functionalized nanomaterials: innovative therapeutic avenues for Alzheimer's disease management","author":"Pei","year":"2025","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.exer.2025.110395_bib59","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.3389\/fimmu.2018.01694","article-title":"C5a-preactivated neutrophils are critical for autoimmune-induced astrocyte dysregulation in neuromyelitis optica spectrum disorder","volume":"9","author":"Piatek","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.exer.2025.110395_bib60","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4\u2013positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.exer.2025.110395_bib61","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1177\/13524585211038291","article-title":"Eculizumab monotherapy for NMOSD: data from PREVENT and its open-label extension","volume":"28","author":"Pittock","year":"2022","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.exer.2025.110395_bib62","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","article-title":"Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study","volume":"12","author":"Pittock","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.exer.2025.110395_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102544","article-title":"Stressful life events, socioeconomic status, and the risk of neuromyelitis optica spectrum disorder: a population-based case-control study","volume":"46","author":"Rafiee","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.exer.2025.110395_bib64","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/jamaneurol.2015.0533","article-title":"Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder","volume":"72","author":"Ringelstein","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.exer.2025.110395_bib65","article-title":"Interleukin-6 receptor blockade in treatment-refractory MOG-IgG\u2013associated disease and neuromyelitis optica spectrum disorders","volume":"9","author":"Ringelstein","year":"2021","journal-title":"Neurology: Neuroimmunol. Neuroinflammation"},{"key":"10.1016\/j.exer.2025.110395_bib66","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/ana.22686","article-title":"Neutrophil protease inhibition reduces neuromyelitis optica\u2013immunoglobulin G\u2013induced damage in mouse brain","volume":"71","author":"Saadoun","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.exer.2025.110395_bib67","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a032037","article-title":"B-cell therapies in multiple sclerosis","volume":"9","author":"Sabatino","year":"2019","journal-title":"Cold Spring Harb. Perspect Med."},{"key":"10.1016\/j.exer.2025.110395_bib68","doi-asserted-by":"crossref","first-page":"25800","DOI":"10.1073\/pnas.1915309116","article-title":"Anti-CD20 therapy depletes activated myelin-specific CD8+ T cells in multiple sclerosis","volume":"116","author":"Sabatino","year":"2019","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.exer.2025.110395_bib69","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1590\/S0004-282X2011000600019","article-title":"Atypical presentations of neuromyelitis optica","volume":"69","author":"Sato","year":"2011","journal-title":"Arquivos de neuro-psiquiatria"},{"key":"10.1016\/j.exer.2025.110395_bib70","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3748\/wjg.v20.i3.613","article-title":"Helicobacter pylori and autoimmune disease: cause or bystander","volume":"20","author":"Smyk","year":"2014","journal-title":"World J. Gastroenterol.: WJG"},{"key":"10.1016\/j.exer.2025.110395_bib71","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1177\/1759720X10378372","article-title":"The role of interleukin 6 in the pathophysiology of rheumatoid arthritis","volume":"2","author":"Srirangan","year":"2010","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"10.1016\/j.exer.2025.110395_bib72","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1093\/rheumatology\/kes131","article-title":"Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study","volume":"51","author":"Strand","year":"2012","journal-title":"Rheumatology"},{"key":"10.1016\/j.exer.2025.110395_bib73","series-title":"Aquaporin 4-specific T Cells in Neuromyelitis Optica Exhibit a Th17 Bias and Recognize Clostridium ABC Transporter","author":"Stroud","year":"2012"},{"key":"10.1016\/j.exer.2025.110395_bib74","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/ana.22657","article-title":"Anti\u2013Aquaporin\u20104 monoclonal antibody blocker therapy for neuromyelitis optica","volume":"71","author":"Tradtrantip","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.exer.2025.110395_bib75","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1177\/1352458510379247","article-title":"Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6","volume":"16","author":"Uzawa","year":"2010","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.exer.2025.110395_bib76","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1007\/s00415-009-5274-4","article-title":"Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis","volume":"256","author":"Uzawa","year":"2009","journal-title":"J. Neurol."},{"key":"10.1016\/j.exer.2025.110395_bib77","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.660382","article-title":"Autoantibodies against the complement regulator factor h in the serum of patients with neuromyelitis optica spectrum disorder","volume":"12","author":"Uzonyi","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.exer.2025.110395_bib78","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1177\/1352458510380416","article-title":"Preferential increase of B-cell activating factor in the cerebrospinal fluid of neuromyelitis optica in a white population","volume":"16","author":"Vaknin-Dembinsky","year":"2010","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.exer.2025.110395_bib79","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/ana.23651","article-title":"Aquaporin 4\u2010specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize clostridium ABC transporter","volume":"72","author":"Varrin\u2010Doyer","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.exer.2025.110395_bib80","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.molimm.2013.09.010","article-title":"A systematic analysis of the complement pathways in patients with neuromyelitis optica indicates alteration but no activation during remission","volume":"57","author":"Veszeli","year":"2014","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.exer.2025.110395_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.indcrop.2024.119191","article-title":"Ant colony algorithm-enabled back propagation neural network and response surface methodology based ultrasonic optimization of safflower seed alkaloid extraction and antioxidant","volume":"220","author":"Wan","year":"2024","journal-title":"Ind. Crop. Prod."},{"key":"10.1016\/j.exer.2025.110395_bib82","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1159\/000339302","article-title":"Notable increased cerebrospinal fluid levels of soluble interleukin-6 receptors in neuromyelitis optica","volume":"19","author":"Wang","year":"2012","journal-title":"Neuroimmunomodulation"},{"key":"10.1016\/j.exer.2025.110395_bib83","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jocn.2010.05.030","article-title":"The rescue effect of plasma exchange for neuromyelitis optica","volume":"18","author":"Wang","year":"2011","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.exer.2025.110395_bib84","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1007\/s00415-017-8445-8","article-title":"What's new in neuromyelitis optica? A short review for the clinical neurologist","volume":"264","author":"Whittam","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.exer.2025.110395_bib85","first-page":"105","article-title":"Neuromyelitis optica spectrum disorders","volume":"16","author":"Wingerchuk","year":"2010","journal-title":"Continuum"},{"key":"10.1016\/j.exer.2025.110395_bib86","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic's syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.exer.2025.110395_bib87","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.exer.2025.110395_bib88","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMra1904655","article-title":"Neuromyelitis optica spectrum disorder","volume":"387","author":"Wingerchuk","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.exer.2025.110395_bib89","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jneuroim.2017.07.006","article-title":"Anti-C1q autoantibodies in patients with neuromyelitis optica spectrum disorders","volume":"310","author":"Yoshikura","year":"2017","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.exer.2025.110395_bib90","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s13311-017-0594-z","article-title":"The gut microbiome in neuromyelitis optica","volume":"15","author":"Zamvil","year":"2018","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.exer.2025.110395_bib91","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.5588\/ijtld.10.0780","article-title":"Neuromyelitis optica and pulmonary tuberculosis: a case-control study","volume":"15","author":"Zatjirua","year":"2011","journal-title":"Int. J. Tubercul. Lung Dis."},{"key":"10.1016\/j.exer.2025.110395_bib92","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s40120-021-00279-8","article-title":"Hematoma evacuation via image-guided para-corticospinal tract approach in patients with spontaneous intracerebral hemorrhage","volume":"10","author":"Zhang","year":"2021","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.exer.2025.110395_bib93","doi-asserted-by":"crossref","first-page":"33032","DOI":"10.1021\/acsnano.4c05693","article-title":"Multi targeted therapy for Alzheimer's disease by guanidinium-modified calixarene and cyclodextrin co-assembly loaded with insulin","volume":"18","author":"Zhang","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.exer.2025.110395_bib94","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1177\/1352458514522103","article-title":"Neuropathic pain in neuromyelitis optica affects activities of daily living and quality of life","volume":"20","author":"Zhao","year":"2014","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.exer.2025.110395_bib95","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nri2620","article-title":"Complement regulators and inhibitory proteins","volume":"9","author":"Zipfel","year":"2009","journal-title":"Nat. Rev. Immunol."}],"updated-by":[{"DOI":"10.1016\/j.exer.2025.110637","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000}}],"container-title":["Experimental Eye Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483525001666?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483525001666?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T20:10:21Z","timestamp":1747944621000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014483525001666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":95,"alternative-id":["S0014483525001666"],"URL":"https:\/\/doi.org\/10.1016\/j.exer.2025.110395","relation":{},"ISSN":["0014-4835"],"issn-type":[{"value":"0014-4835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune-related biomarkers in the neuromyelitis optica spectrum disorder; pathogenesis and therapeutic approaches","name":"articletitle","label":"Article Title"},{"value":"Experimental Eye Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exer.2025.110395","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"110395"}}